NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

39.72M

Vuru Grade

23.16/100

Current Price

$0.65
+0.02 (+3.98%)

Stability Price

$0.30
Overvalued by 54.58%

Company Metrics

  • 0 P/E
  • 36.24 P/S
  • 17.36 P/B
  • -0.31 EPS
  • -2,078.99% Cash ROIC
  • 1.62 Cash Ratio
  • 0 / 0% Dividend
  • 328,733.00 Avg. Vol.
  • 49.63M Shares
  • 39.72M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Short Interest Up 15.1% in April (NBY)
Dakota Financial News - 8 hours ago
Shares of NovaBay Pharmaceuticals (NYSE:NBY) traded up 0.0000% on Monday, hitting $0.6251. 147,372 shares of the company's stock traded hands. NovaBay Pharmaceuticals has a 52-week low of $0.4200 and a 52-week high of $1.3000. The stock has ...
What's Hot Today: Weibo Corporation (NASDAQ:WB), NovaBay ... - Property Mentor
NovaBay Pharmaceuticals Seeks To Change The Paradigm Of Eye Care From ...
Seeking Alpha - Apr 21, 2015
NovaBay hopes Avenova will usher in a monumental change in the way that we care for our eyes that mirrors the way we care for our teeth.
NovaBay Signs Distribution Agreement with AmerisourceBergen Corporation for ...
Benzinga - Apr 16, 2015
NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the commercialization and development of its non-antibiotic anti-infective products, announces that it has signed a nationwide distribution agreement with ...
Bears of the Day: NovaBay Pharmaceuticals, (NYSEMKT:NBY), Ultra Clean ...
wsnewspublishers - Apr 22, 2015
NovaBay Pharmaceuticals, Inc. (NBY) declared that the registration statement on Form S-3 associated with the Company's March 2015 private placement has been declared effective by the U.S.
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek Chairman
Business Wire (press release) - Apr 14, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces the ...
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Appoints Mark M ... - The Wall Street Transcript
Form 8-K NovaBay Pharmaceuticals, For: Apr 10
StreetInsider.com - Apr 14, 2015
On April 10, 2015, the NovaBay Pharmaceuticals, Inc. Board of Directors appointed Mark M. Sieczkarek as the Chairman of the Board of NovaBay.
NovaBay Pharmaceuticals' (NBY) CEO Ron Najafi on Q4 2014 - Earnings Call ...
Seeking Alpha (registration) - Mar 27, 2015
NovaBay Pharmaceuticals' (NBY) CEO Ron Najafi on Q4 2014 - Earnings Call Transcript. Mar. 26, 2015 8:39 PM ET | About: NovaBay Pharmaceuticals, Inc. (NBY) by: SA Transcripts. NovaBay Pharmaceuticals Inc. (NYSEMKT:NBY). Q4 2014 Earnings ...
NovaBay Pharmaceuticals Reports 2014 Fourth Quarter and Full Year Financial ... - Business Wire (press release)
NovaBay revamps strategy to focus on Eye Care (NBY)
Seeking Alpha - Jan 7, 2015
NovaBay Pharmaceuticals (NYSEMKT:NBY) refines its business strategy in order to focus on the eye care market. Its initiative consists of three main components: Drive revenue growth by by expanding the sales and marketing organization.
NovaBay Announces New Business Strategy Focusing on Products for Eye Care - Yahoo Finance UK
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth
Business Wire (press release) - Mar 16, 2015
BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today provided an update on its commercial ...
NovaBay Pharmaceuticals Signs Avenova and NeutroPhase Distribution ...
Business Wire (press release) - Mar 9, 2015
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products, today announced that it has signed two new ...